Clinical trials: Myeloproliferative Diseases
Myeloproliferative Neoplasm (MPN), Pregnancy
Study of Pregnancy in Patients With Myeloproliferative Neoplasms
This is a study to evaluate pregnancy in patients with myeloproliferative neoplasms. The main endpoint of this study is to determine the number of live births in pregnant MPN patients who are managed by a risk-adapted algorithm
- Trial name
- NCT07832513
- Testing
- Risk-adapted algorithm
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Myelofibrosis，MF
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
The goal of this open-label, single-center, pilot trial is to test the combination of Tagraxofusp (TAG) with Pacritinib (PAC) in patients with intermediate-II or higher myelofibrosis (MF), who have had prior therapy with the…
- Trial name
- NCT06414681
- Testing
- Tagraxofusp, Pacritinib
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Chronic Myeloid Leukemia
Allogeneic SCT for CML, TKI Failure After TKI Failure
The investigators will evaluate the outcomes of allogeneic stem cell transplantation which is the only curative treatment modality in the patients with chronic myeloid leukemia after failing tyrosine kinase inhibitor therapy.
- Trial name
- NCT02172365
- Where
- Canada
- Volunteers
- 350 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00807677
- Testing
- TAK-901
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Determine the safety and tolerability of POL6326 when used as a single mobilization agent.
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission
- Trial name
- NCT01413568
- Testing
- POL6326, Leukapheresis, PBSC Transplant
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Polyphor Ltd.
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Leukemia,Myeloid, Chronic
Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity.
- Trial name
- MICROBIO-LMC (NCT06724536)
- Testing
- non interventional study with the use of biological samples.
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Carmen Fava
Leukemia
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
RATIONALE: Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT01020734
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 263 people
- Sponsor
- Asan Medical Center
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Non-randomized, open, dose ranging and dose scheduling study of ascending doses of KW-2449 in subjects with AML, ALL, MDS and CML.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT00346632
- Testing
- KW-2449
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Kyowa Kirin, Inc.
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00301834
- Testing
- alemtuzumab, busulfan, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Polycythemia Vera
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and…
- Trial name
- PEGINVERA (NCT01193699)
- Testing
- PEG-P-INF alpha-2b (P1101)
- Where
- 6 sites in Austria
- Volunteers
- 24 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Polycythemia Vera
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Clopidogrel (Plavix) and aspirin are two antithrombotic agents (blood thinners) commonly used in patients with previous thrombotic events (stroke or heart attack). Thrombosis is the formation of a blood clot in a blood vessel.
- Trial name
- ISCLAP (NCT00940784)
- Testing
- Clopidogrel (Plavix), Aspirin
- Sponsor
- Ronald Hoffman
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006084
- Testing
- lintuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia, Myelofibrosis
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
The goal of this clinical research study is to learn if rigosertib can help to control MF in patients with anemia. The safety of this drug will also be studied. This is an investigational study.
- Conditions
- Leukemia, Myelofibrosis, Anemia, Splenomegaly
- Trial name
- NCT02730884
- Testing
- Rigosertib, Questionnaire
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
This phase I trial is studying the side effects and best dose of tanespimycin when given with cytarabine in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00098423
- Testing
- tanespimycin, cytarabine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.
- Trial name
- NCT02317159
- Testing
- Imatinib
- Volunteers
- 90 people
- Sponsor
- Cttq
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00040846
- Testing
- alemtuzumab, fludarabine phosphate, total-body irradiation
- Where
- 7 sites in United States, Italy
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03333486
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.